COEPTIS THERAPEUTICS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3832 USD | +4.70% |
|
+6.44% | -51.12% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | - | 50.51 | 29.89 | 26.74 |
| Enterprise Value (EV) 1 | - | 52.41 | 27.8 | 26.49 |
| P/E ratio | -6.78 x | -8.12 x | -0.58 x | -0.95 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 673 x | - | - |
| EV / Revenue | - | 699 x | - | - |
| EV / EBITDA | - | -3.85 x | -0.84 x | -1.29 x |
| EV / FCF | - | -17,201,448 x | 3,473,509 x | -3,827,473 x |
| FCF Yield | - | -0% | 0% | -0% |
| Price to Book | -49.9 x | 52.7 x | 6.24 x | 6.42 x |
| Nbr of stocks (in thousands) | - | 12,472 | 19,516 | 34,108 |
| Reference price 2 | 10.19 | 10.00 | 1.531 | 0.7839 |
| Announcement Date | 04/02/22 | 11/03/22 | 29/03/23 | 26/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.2832 | 0.7241 | 0.0308 | 0.075 | - | - |
| EBITDA 1 | -1.888 | -3.705 | -6.39 | -13.6 | -33.19 | -20.49 |
| EBIT 1 | -1.891 | -3.707 | -6.713 | -14.05 | -34.2 | -21.49 |
| Operating Margin | -667.66% | -512.02% | -21,823.77% | -18,727.91% | - | - |
| Earnings before Tax (EBT) 1 | -1.891 | -1.406 | -9.156 | -13.45 | -37.57 | -21.27 |
| Net income 1 | -1.891 | -1.406 | -9.156 | -13.45 | -37.57 | -21.27 |
| Net margin | -667.66% | -194.17% | -29,765.9% | -17,932.37% | - | - |
| EPS 2 | -0.3737 | -0.2735 | -1.503 | -1.232 | -2.628 | -0.8278 |
| Free Cash Flow | - | -0.0972 | 1.052 | -3.047 | 8.004 | -6.922 |
| FCF margin | - | -13.42% | 3,418.86% | -4,062.69% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 12/02/21 | 12/02/21 | 04/02/22 | 11/03/22 | 29/03/23 | 26/03/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA | - | - | - | - |
| EBIT 1 | - | -3.595 | -7.812 | -3.541 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.113 | -6.261 | -4.024 |
| Net income 1 | - | -3.113 | -6.261 | -4.024 |
| Net margin | - | - | - | - |
| EPS 2 | -0.3900 | -0.1400 | -0.2300 | -0.0800 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 15/05/23 | 11/08/23 | 09/11/23 | 26/03/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 1.88 | 1.9 | - | - |
| Net Cash position 1 | 0.25 | 0.15 | - | - | 2.08 | 0.24 |
| Leverage (Debt/EBITDA) | - | - | -0.295 x | -0.1399 x | - | - |
| Free Cash Flow | - | -0.1 | 1.05 | -3.05 | 8 | -6.92 |
| ROE (net income / shareholders' equity) | - | 568% | 405% | 963% | -1,050% | -485% |
| ROA (Net income/ Total Assets) | - | -166% | -452% | -248% | -291% | -168% |
| Assets 1 | - | 0.848 | 2.028 | 5.413 | 12.91 | 12.66 |
| Book Value Per Share 2 | -0.3200 | 0.0700 | -0.2000 | 0.1900 | 0.2500 | 0.1200 |
| Cash Flow per Share 2 | 0.2400 | 0.0300 | 0.0100 | 0.1800 | 0.1900 | 0.0400 |
| Capex 1 | 0 | 0 | - | - | - | - |
| Capex / Sales | 0.99% | 0% | - | - | - | - |
| Announcement Date | 12/02/21 | 12/02/21 | 04/02/22 | 11/03/22 | 29/03/23 | 26/03/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3832
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| -51.12% | 13.83M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- COEP Stock
- Financials Coeptis Therapeutics Holdings, Inc.
